Sharon M Cawley
Acceleron Pharma (United States)(US)
Publications by Year
Research Areas
Nitric Oxide and Endothelin Effects, Hemoglobinopathies and Related Disorders, Receptor Mechanisms and Signaling, Phosphodiesterase function and regulation, Iron Metabolism and Disorders
Most-Cited Works
- → Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis(2014)425 cited
- → Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia(2014)142 cited
- → sGCα1β1attenuates cardiac dysfunction and mortality in murine inflammatory shock models(2009)49 cited
- → Nitric oxide-evoked transient kinetics of cyclic GMP in vascular smooth muscle cells(2006)41 cited
- → sGCα1 mediates the negative inotropic effects of NO in cardiac myocytes independent of changes in calcium handling(2011)33 cited
- → Cygnets: In Vivo Characterization of Novel cGMP Indicators and In Vivo Imaging of Intracellular cGMP(2005)27 cited
- → Nitric oxide synthase 3 deficiency limits adverse ventricular remodeling after pressure overload in insulin resistance(2011)8 cited
- → Trastuzumab and lapatinib differ in effects on calcium cycling and HER2 expression in human embryonic stem cell-derived cardiomyocytes(2013)5 cited
- → ACE-536 Improves Ineffective Erythropoiesis, Anemia and Co-Morbidities in β-Thalassemia(2012)2 cited
- → TGFb1 Antagonist Inhibits Fibrosis in a Murine Model of Myelofibrosis(2015)1 cited